Adaptive Biotechnologies

Learn more

Read the press release

Now providing you the powerful tools you need to fully understand the T-cell response in COVID-19

NOW AVAILABLE

For Research Use Only. Not for use in diagnostic procedures.

Learn more about the data

Read the press release

ImmuneCODE™ Launched

De-identified COVID-19 immune response data available to help accelerate solutions to the pandemic

416,556,789 TCRs Sequenced

3,189 Samples

Learn more

Developing Therapeutic Antibodies Against COVID-19

Every immune system has a story to tell.

The key is knowing how to listen.

At Adaptive, we’re writing the next chapter of precision health — powered by immune-driven medicine.

Learn more

Read our press release

clonoSEQ is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies for use in acute lymphoblastic leukemia and multiple myeloma patients to detect measurable residual disease (MRD) in human bone marrow samples. clonoSEQ is also available for use in other lymphoid cancers as a CLIA-regulated laboratory developed test (LDT) service provided by Adaptive Biotechnologies. clonoSEQ is only available by prescription from a licensed healthcare professional. For important information about the FDA-cleared clonoSEQ IVD test service, including the full intended use, limitations, and detailed performance characteristics, please visit clonoSEQ.com/IFU.